InSilico Medicine Cayman TopCo (HKG:3696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
62.15
-5.85 (-8.60%)
At close: Feb 6, 2026
77.57%
Market Cap35.42B
Revenue (ttm)420.77M +77.8%
Net Income-348.07M
EPS-4.68
Shares Out569.97M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,133,100
Average Volume2,843,132
Open65.45
Previous Close68.00
Day's Range61.50 - 67.95
52-Week Range29.98 - 72.40
Betan/a
RSI62.74
Earnings Daten/a

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ... [Read more]

Sector Technology
Founded 2014
Employees 319
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3696
Full Company Profile

Financial Performance

In 2024, HKG:3696's revenue was $85.83 million, an increase of 67.71% compared to the previous year's $51.18 million. Losses were -$17.10 million, -91.92% less than in 2023.

Financial numbers in USD Financial Statements